157PShort-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms. (23rd October 2018) - Fan, Y; Xu, Y; Tong, X; Yan, J; Wu, X; Shao, Y W